{"id":"evaluated-vaccine","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without additional specification of the vaccine type (inactivated, live attenuated, mRNA, protein subunit, viral vector, etc.) or target pathogen, the precise immunological mechanism cannot be accurately described. Vaccines generally work by presenting antigens to the immune system to generate adaptive immunity against specific infectious agents.","oneSentence":"An evaluated vaccine formulation developed by Beijing CDC that stimulates immune response, though the specific antigen target and mechanism require clarification.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:46:04.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07495202","phase":"PHASE1","title":"A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JunTop Biosciences Co., LTD","startDate":"2026-03-30","conditions":"Health Volunteer","enrollment":180},{"nctId":"NCT06417853","phase":"PHASE1","title":"Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)","status":"COMPLETED","sponsor":"Vaxxas Pty Ltd","startDate":"2024-07-31","conditions":"H7N9 Influenza","enrollment":267},{"nctId":"NCT07496450","phase":"PHASE3","title":"A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT02772003","phase":"PHASE1","title":"DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-06","conditions":"Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT05652504","phase":"PHASE1","title":"Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Malaria","enrollment":400},{"nctId":"NCT07407569","phase":"PHASE2","title":"Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2026-03-25","conditions":"Human Papilloma Virus Infection Type 16","enrollment":50},{"nctId":"NCT06745921","phase":"PHASE1","title":"Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-24","conditions":"West Nile Viral Infection","enrollment":30},{"nctId":"NCT05642195","phase":"PHASE1, PHASE2","title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT05703607","phase":"PHASE1, PHASE2","title":"A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-01-25","conditions":"Shingles, Herpes Zoster Infection, Human","enrollment":485},{"nctId":"NCT07204964","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-07","conditions":"Influenza, Human","enrollment":971},{"nctId":"NCT06735209","phase":"PHASE1","title":"First-in-Human PfSPZ-LARC2 Vaccination/CHMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-23","conditions":"Malaria","enrollment":22},{"nctId":"NCT02639299","phase":"","title":"Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-08","conditions":"Malaria","enrollment":1500},{"nctId":"NCT05642429","phase":"PHASE1","title":"Study of AV-1959D, an Amyloid Beta Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute for Molecular Medicine","startDate":"2023-02-27","conditions":"Alzheimer Disease","enrollment":48},{"nctId":"NCT00001539","phase":"","title":"A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1996-06-13","conditions":"Lyme Disease","enrollment":700},{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT07492303","phase":"PHASE1","title":"A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-04-20","conditions":"Pertussis (Whooping Cough), Diphtheria, Tetanus","enrollment":96},{"nctId":"NCT04381689","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-10-23","conditions":"Healthy","enrollment":245},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT07492706","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2026-04-01","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":120},{"nctId":"NCT07300085","phase":"PHASE1","title":"A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cidara Therapeutics Inc.","startDate":"2025-11-08","conditions":"Healthy Participants","enrollment":100},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT07478952","phase":"PHASE1","title":"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-17","conditions":"Epstein-Barr Virus","enrollment":120},{"nctId":"NCT06684431","phase":"PHASE1","title":"Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2024-11-12","conditions":"Crimean Congo Hemorrhagic Fever","enrollment":15},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT03091660","phase":"PHASE3","title":"S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2017-02-24","conditions":"Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma","enrollment":1000},{"nctId":"NCT06832410","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-03-31","conditions":"Type 1 Diabetes, Kidney Transplant","enrollment":10},{"nctId":"NCT07431853","phase":"PHASE2","title":"A Study to Learn About mRNA Vaccines Against Influenza in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-23","conditions":"Healthy Adults","enrollment":770},{"nctId":"NCT07485283","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia","status":"NOT_YET_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2026-03","conditions":"Cardiovascular Disease, Dementia","enrollment":162000},{"nctId":"NCT01375530","phase":"","title":"Screening Volunteers for Clinical Trials","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-08-16","conditions":"Screening","enrollment":4000},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT06950645","phase":"PHASE1","title":"The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-03-27","conditions":"Rotavirus Gastroenteritis","enrollment":100},{"nctId":"NCT06652737","phase":"PHASE1","title":"Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanaria Inc.","startDate":"2025-03-04","conditions":"Malaria Falciparum, Malaria Infection","enrollment":75},{"nctId":"NCT07300267","phase":"PHASE1","title":"A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-13","conditions":"Pneumococcal Infection","enrollment":210},{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440},{"nctId":"NCT04732871","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-02-15","conditions":"Respiratory Syncytial Virus Infections","enrollment":1720},{"nctId":"NCT07013487","phase":"PHASE3","title":"A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-11","conditions":"Healthy","enrollment":12000},{"nctId":"NCT06669208","phase":"PHASE1","title":"Trial of an Inactivated Chikungunya Virus Vaccine","status":"COMPLETED","sponsor":"Najit Technologies, Inc.","startDate":"2024-11-04","conditions":"Chikungunya Fever, Chikungunya Virus, Chikungunya","enrollment":48},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT05879965","phase":"","title":"Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2022-10-06","conditions":"Monkeypox","enrollment":345},{"nctId":"NCT06719219","phase":"PHASE1","title":"A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2025-01-07","conditions":"Staphylococcus (S.) Aureus Infection","enrollment":129},{"nctId":"NCT03462004","phase":"PHASE1","title":"Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-03-05","conditions":"Ebola Virus Disease","enrollment":15},{"nctId":"NCT07425392","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-02-09","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT05547464","phase":"PHASE1, PHASE2","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2023-07-31","conditions":"Tuberculosis","enrollment":497},{"nctId":"NCT06077656","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2023-10-25","conditions":"Pneumococcal Vaccines","enrollment":220},{"nctId":"NCT06833957","phase":"","title":"Preparing for Maternal GBS Vaccine Trials in Africa","status":"RECRUITING","sponsor":"Barcelona Institute for Global Health","startDate":"2025-03-01","conditions":"Group B Streptococcus, Invasive Bacterial Diseases (IBD), Maternal Immunization","enrollment":18100},{"nctId":"NCT04298606","phase":"EARLY_PHASE1","title":"A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2021-11-22","conditions":"Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma, Pneumonia","enrollment":20},{"nctId":"NCT05846516","phase":"PHASE1","title":"A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2023-05-11","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":58},{"nctId":"NCT06927297","phase":"PHASE1","title":"Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-05-09","conditions":"Advanced Solid Tumor Malignancies, Advanced Solid Malignancies","enrollment":12},{"nctId":"NCT05923970","phase":"","title":"Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2024-11-09","conditions":"Vaccination Failure, Vaccine Response Impaired","enrollment":200},{"nctId":"NCT07467707","phase":"PHASE3","title":"An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults","status":"NOT_YET_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2026-05","conditions":"Chikungunya Virus","enrollment":6144},{"nctId":"NCT06692907","phase":"PHASE2","title":"Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-31","conditions":"Escherichia Infection","enrollment":72},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":"COVID-19","enrollment":285000},{"nctId":"NCT05528952","phase":"PHASE2","title":"Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-09-27","conditions":"Hepatocellular Carcinoma","enrollment":105},{"nctId":"NCT07473999","phase":"","title":"Factors Affecting Vaccine Prophylaxis Efficacy in Bone Marrow and Solid Organ Transplant Recipients: Impact on Infection and Mortality Rates","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2019-09-13","conditions":"Vaccine Prophylaxis","enrollment":200},{"nctId":"NCT05683457","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-04-05","conditions":"Cytomegalovirus Infection","enrollment":224},{"nctId":"NCT07284654","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2025-12-01","conditions":"Pneumococcal Vaccines","enrollment":4000},{"nctId":"NCT06926062","phase":"NA","title":"Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Human Papillomavirus-Related Carcinoma","enrollment":1900},{"nctId":"NCT06688058","phase":"PHASE1","title":"A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Healthy","enrollment":72},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT03943875","phase":"PHASE4","title":"GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2019-06-17","conditions":"Immunization, Efficacy, Human Papilloma Virus","enrollment":767},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT06134648","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-11-01","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus","enrollment":646},{"nctId":"NCT07023081","phase":"PHASE1","title":"A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-06-15","conditions":"Pneumococcal Disease","enrollment":200},{"nctId":"NCT05947890","phase":"PHASE2","title":"Evaluating the Safety and Immunogenicity of MTBVAC","status":"RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2024-01-30","conditions":"HIV I Infection, Tuberculosis","enrollment":276},{"nctId":"NCT02410733","phase":"PHASE1","title":"Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2015-03","conditions":"Melanoma","enrollment":119},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06622109","phase":"","title":"A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-11-25","conditions":"Pneumococcal Disease","enrollment":1100},{"nctId":"NCT06177912","phase":"PHASE3","title":"A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-18","conditions":"Pneumococcal Infection","enrollment":882},{"nctId":"NCT07280741","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-02","conditions":"Autoimmune Rheumatic Diseases","enrollment":200},{"nctId":"NCT06531538","phase":"PHASE2","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-07-30","conditions":"Pneumococcal Disease","enrollment":225},{"nctId":"NCT06229392","phase":"PHASE1","title":"A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2026-06-01","conditions":"Breast Cancer, Breast Cancer Triple Negative","enrollment":""},{"nctId":"NCT07460154","phase":"NA","title":"Structured Review: To Optimise Management and Prevent Harm in COPD","status":"NOT_YET_RECRUITING","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2026-03-01","conditions":"COPD","enrollment":96},{"nctId":"NCT05446740","phase":"PHASE1","title":"A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-08-09","conditions":"Influenza, Human","enrollment":324},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT07293065","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-12-15","conditions":"Herpes Zoster","enrollment":12000},{"nctId":"NCT06050356","phase":"PHASE1","title":"First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b","status":"ACTIVE_NOT_RECRUITING","sponsor":"Statens Serum Institut","startDate":"2024-03-14","conditions":"Healthy","enrollment":140},{"nctId":"NCT06251024","phase":"PHASE2","title":"Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-02","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers","enrollment":4541},{"nctId":"NCT07220109","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":750},{"nctId":"NCT06805487","phase":"PHASE1","title":"Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-24","conditions":"Zika Virus","enrollment":27},{"nctId":"NCT06534892","phase":"PHASE3","title":"An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-08-01","conditions":"Respiratory Syncytial Virus Infections","enrollment":10212},{"nctId":"NCT05580458","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-13","conditions":"Herpes Zoster","enrollment":225},{"nctId":"NCT07457060","phase":"PHASE4","title":"Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-11-27","conditions":"Poliomyelitis","enrollment":480},{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT06891950","phase":"PHASE3","title":"Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)","status":"RECRUITING","sponsor":"Butantan Institute","startDate":"2026-03-03","conditions":"Dengue","enrollment":997},{"nctId":"NCT07092865","phase":"PHASE2","title":"A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-06","conditions":"Respiratory Syncytial Virus Infections","enrollment":184},{"nctId":"NCT00050310","phase":"","title":"Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-10-31","conditions":"Anthrax, Bacillus Infections","enrollment":200},{"nctId":"NCT07455318","phase":"PHASE3","title":"Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2026-05-15","conditions":"Rabies (Healthy Volunteers)","enrollment":561},{"nctId":"NCT06272812","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.","status":"RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2025-02-19","conditions":"Tuberculosis (TB)","enrollment":5500},{"nctId":"NCT06973772","phase":"PHASE3","title":"Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.","status":"NOT_YET_RECRUITING","sponsor":"Butantan Institute","startDate":"2026-03-31","conditions":"Dengue, Chikungunya","enrollment":900},{"nctId":"NCT06485258","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2024-08-06","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06962904","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2025-07-07","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06036602","phase":"PHASE2","title":"Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2024-07-15","conditions":"Ebola Sudan Virus Disease","enrollment":125},{"nctId":"NCT07446166","phase":"NA","title":"TETANUS Antibody Detection in Saliva Study","status":"NOT_YET_RECRUITING","sponsor":"University of Birmingham","startDate":"2026-02-01","conditions":"Tetanus","enrollment":390},{"nctId":"NCT05854381","phase":"PHASE1","title":"To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-09-19","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT07445815","phase":"PHASE2","title":"A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody","status":"NOT_YET_RECRUITING","sponsor":"Lanzhou Institute of Biological Products Co., Ltd","startDate":"2026-01-31","conditions":"Rabies (Healthy Volunteers)","enrollment":200},{"nctId":"NCT07447245","phase":"NA","title":"Parent Education About Human Papillomavirus (HPV)","status":"RECRUITING","sponsor":"KTO Karatay University","startDate":"2026-02-15","conditions":"HPV (Human Papillomavirus)-Associated","enrollment":52},{"nctId":"NCT03855995","phase":"","title":"A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-03-21","conditions":"Malaria, Malaria Vaccines","enrollment":77953},{"nctId":"NCT05569954","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-07","conditions":"Pneumococcal Disease","enrollment":1484}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":108,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"evaluated vaccine","genericName":"evaluated vaccine","companyName":"Beijing Center for Disease Control and Prevention","companyId":"beijing-center-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}